Today, the EVP & COO of Cambrex Corp (NYSE: CBM), Shawn Cavanagh, bought shares of CBM for $1.43M.
Following Shawn Cavanagh’s last CBM Buy transaction on May 09, 2018, the stock climbed by 14.3%. This is Cavanagh’s first Buy trade following 8 Sell transactions.
See today’s analyst top recommended stocks >>
Based on Cambrex Corp’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $152 million and quarterly net profit of $40.42 million. In comparison, last year the company earned revenue of $135 million and had a net profit of $25.03 million. CBM’s market cap is $2.07B and the company has a P/E ratio of 17.51. Currently, Cambrex Corp has an average volume of 316.7K.
Starting in August 2013, CBM received 9 Buy ratings in a row. Five different firms, including Craig-Hallum and Jefferies, currently also have a Buy rating on the stock.
In the last 30 days, insiders have sold $9.61M worth of CBM shares and purchased $3.3M worth of CBM shares. The insider sentiment on Cambrex Corp has been neutral according to 29 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cambrex Corp. engages in the provision of products, services, and technologies to accelerate and improve the development and commercialization of new and generic therapeutics. It supplies to innovator and generic pharmaceutical companies.
